Adrenocortical carcinoma (ACC) is a rare, aggressive malignancy with incidence of 0.7 to 2 cases per million annually \[[@CIT0001]\]. ACC presents across the age spectrum with peaks in children less than 5 years and in adults in their fourth and fifth decade of life \[[@CIT0001]\]. The prognosis is poor, as the majority of patients present with regional and distant metastasis at the time of diagnosis. Long-term survivors, however, are occasionally reported. Clinically, Ki67 immunohistochemistry has been used as the primary prognostic biomarker. Recent global profiling of ACC tumors has demonstrated that comprehensive genomic and genetic signature clusters correlate with ACC tumor aggressiveness, but this clustering has not been used prospectively and may be cumbersome for clinical practice \[[@CIT0002]\].

Common sites of metastasis for ACC include the liver, lungs, and bone \[[@CIT0001]\]. Rarely ACC metastasizes to skin and brain \[[@CIT0001]\]. Leptomeningeal carcinomatous metastases (LM) across all tumor types typically present as multifocal lesions in the leptomeninges in less than 5% of patients with advanced cancer \[[@CIT0003]\]. The most common solid tumors to result in LM include breast, lung, melanoma, and gastrointestinal malignancies \[[@CIT0003]\]. There have been few case reports of ACC resulting in brain metastasis \[[@CIT0004]\] and there are only 2 previous ACC cases with leptomeningeal metastases reported in the literature \[[@CIT0017], [@CIT0018]\].

Here we present the case of a young woman who presented with severe Cushing's syndrome due to ACC with rapid disease progression and LM despite conventional therapy.

1. Material and Methods {#s1}
=======================

A. Patient Data Collection {#s2}
--------------------------

The institutional review board was approved at the University of Colorado to perform this retrospective study and the patient consented for data collection. A chart review of the patient's history was performed. Tumor characteristics, treatment regimens, and clinical outcome data were collected.

B. Tissue Processing, Real-Time qPCR and Methylation-sensitive Restriction Digest/qPCR {#s3}
--------------------------------------------------------------------------------------

Tumor tissues were harvested and RNA and DNA was extracted using Trizol as previously reported \[[@CIT0019]\] and quantitative polymerase chain reaction (qPCR) performed (all supplementary material and figures are located in a digital research materials repository \[[@CIT0020]\]). Genomic DNA extracted from the patient was subjected to methylation-sensitive restriction digestion using Epitect II Methylation enzyme kit (Qiagen \# 335452) according to the manufacturer's protocol \[[@CIT0021]\]. Following digestion, genomic DNA was amplified for G0S2 using a G0S2 primer mix from Qiagen (\#EPHS101235-1A) and the percent G0S2 methylation was calculated.

C. RNA Sequencing and Data Analysis {#s4}
-----------------------------------

Quantified gene expression data in the HTseq-count \[[@CIT0022]\] format for the Cancer Genome Atlas (TCGA) Adrenocortical Carcinoma cohort \[[@CIT0002]\] was downloaded from the Genomic Data Commons \[[@CIT0023]\]. The patient's (CU-ACC6) RNA-seq sample was quantified using the GDC mRNA Analysis pipeline \[[@CIT0022]\].

2. Results {#s5}
==========

A. Case {#s6}
-------

A 23-year-old woman presented with a 50-pound weight gain over 3 months, diffuse swelling, abdominal bloating, and severe hirsutism, with new-onset hypertension and diabetes mellitus and a blood glucose greater than 400 mg/dL. Prior evaluation for abdominal pain, 8 months earlier, revealed normal computed tomography (CT) of the abdomen/pelvis ([Fig. 1](#F1){ref-type="fig"}). On admission, a CT scan revealed a left adrenal mass measuring 10.1 × 7.9 × 10.8 cm without any signs of direct invasion into other structures, no adenopathy, and a normal right adrenal gland ([Fig. 1](#F1){ref-type="fig"}). Laboratory data on admission are outlined in [Table 1](#T1){ref-type="table"}. Given the rapid onset and size of the adrenal mass and severe cortisol and androgen excess, the patient underwent a left adrenalectomy and nephrectomy. Pathology confirmed ACC Stage 3, pT3pN1Mx with 1/1 lymph node positive with a high Ki67 score of 60% and no detection of abnormalities in mismatch repair proteins ([Fig. 2](#F2){ref-type="fig"}). Postoperatively, the patient was treated with mitotane and adjuvant doxorubicin, etoposide, and carboplatin. The chemotherapy was discontinued after 2 cycles because of neutropenic fever, intra-abdominal abscesses, and pancreatic pseudocysts. Mitotane was continued; however, she was readmitted within a month with recurrence in the left adrenalectomy/nephrectomy bed as well as new liver metastases. Two cycles of palliative carboplatin and paclitaxel were administered. Three months later, the patient presented to the emergency department with a generalized tonic--clonic seizure. Neurological examination at time of presentation was nonfocal. Magnetic resonance imaging of the brain demonstrated leptomeningeal carcinomatosis with parenchymal metastatic disease. She was discharged to hospice care and died shortly after discharge, 11 months from the initial diagnosis.

![The abdominal computed tomography (CT) of the patient at baseline and at presentation only 8 months later revealing a large (10.1 x 7.9 x 10.8 cm) heterogeneous left adrenal mass. Green arrow shows normal adrenal gland; Red arrow shows large ACC mass.](bvaa017f0001){#F1}

###### 

**ACC006 patient laboratory values**.

  Labs           Baseline   Postsurgery   Recurrence    Reference range
  -------------- ---------- ------------- ------------- --------------------------
  TSH            0.85       1.96          0.1           0.34--5.50 mIU/L
  Free T4        0.91       1.61          0.68          0.89--1.76 ng/dL
  Cortisol       65         14            --            4--22 µg/dL
  ACTH           13         20            Not checked   6--58 pg/mL
  DHEAS          949        29            391           65--380 µg/dL
  Testosterone   809        \<20          820           14--76 ng/dL
  Estradiol      --         \<20          --            56--214 pg/mL (midcycle)
  FSH            --         3             --            3--33 mIU/mL (midcycle)

![Immunohistochemistry of ACC006 tumor tissue showing hematoxylin and eosin (H&E), Inhibin alpha, Ki67, and MelanA staining.](bvaa017f0002){#F2}

B. Genetic and Genomic Profiling {#s7}
--------------------------------

To further examine the molecular mechanisms of this aggressive ACC tumor, transcriptome and whole-exome sequencing were performed. In contrast to the majority of ACC tumors, *IGF2* was downregulated in the ACC006 tumor \[[@CIT0020]\]. Hierarchical clustering of this tumor with TCGA ACC samples was performed, and demonstrated that ACC006 clustered with the most aggressive subtype---high proliferative secretory tumors \[[@CIT0020]\]. Whole-exome sequencing revealed only two somatic mutations predicted to be damaging: *TP53* p.V14G and *MEN1* p.E368X, both unfortunately, nonactionable.

C. BUB1B--PINK Score and G0S2 Methylation {#s8}
-----------------------------------------

To test the usefulness of the recently reported ACC molecular biomarkers, we retrospectively analyzed the expression of *BUB1B* (BUB1 Mitotic Checkpoint Serine/Threonine Kinase B) and *PINK1* (PTEN induced kinase 1) in tumor samples. The *BUB1B--PINK1* score was 3.47, supportive of the approach here a score \<5.2 has been associated with the risk for a poor outcome \[[@CIT0024],[@CIT0025]\]. Analysis of methylation status of G0S2, another predictive biomarker, by methylation-sensitive restriction digest/qPCR demonstrated high 97% methylation (20.9 % hypermethylated and 76.9 % intermediate methylation). RNA expression analysis of the G0S2 by qPCR generated a delta Ct value that was undetectable, consistent with the highly methylated status of the gene.

3. Discussion {#s9}
=============

ACC carries a poor prognosis, especially in patients who have distant metastasis at the time of presentation. However, a large variation in overall survival has been reported \[[@CIT0001]\]. Our patient initially presented without metastasis, yet had a very aggressive course, unresponsive to standard therapy. Predicting an aggressive tumor and identifying possible biomarkers can be challenging and is an ongoing area of study.

Intracranial ACC metastasis is very rare, with few cases reported in the literature (roughly 13 cases in adults and 9 cases in children). [Tables 2](#T2){ref-type="table"} and [3](#T3){ref-type="table"} shows the variability in patient presentation with intracranial metastasis. Many of the patients had concomitant lung and liver metastases, the more common sites of metastases in ACC \[[@CIT0001]\]. Our patient was unique in that she had leptomeningeal metastasis, an extremely rare presentation, with only 2 cases previously reported \[[@CIT0017],[@CIT0018]\]. Similar to the patients included in [Tables 2](#T2){ref-type="table"} and [3](#T3){ref-type="table"}, she also had liver and lung metastases at the time of the CNS spread, a mutation in *TP53* and her post-treatment survival was poor. Compared to previous ACC cases with LM, our patient presented with overt Cushing's and similar survival as the pediatric case, whereas the previously reported adult patient had a nonfunctioning tumor and longer survival.

###### 

**Adult patients with ACC and intracranial metastases**.

  Author                                 Age (years)   Gender   Other metastases            Intracranial location    Survival (months)   Functional status   Brain metastasis from initial diagnosis
  -------------------------------------- ------------- -------- --------------------------- ------------------------ ------------------- ------------------- -----------------------------------------
  Seabold et al. (1977) \[[@CIT0012]\]   35            F        Liver and lung              Brain                    −                   −                   \-
  Seabold et al. (1977) \[[@CIT0012]\]   54            M        Liver                       Brain                    −                   Non-functioning     17 months
  Tartour et al. (1993) \[[@CIT0013]\]   60            F        Liver, bone                 Brain                    −                   −                   \-
  Kubota et al. (1997) \[[@CIT0006]\]    47            M        Lung and liver              Brain                    3                   −                   9 months
  Bartley et al. (2001) \[[@CIT0005]\]   24            M        Lung and vertebrae          Orbit/brain              15                  Nonfunctioning      2 years
  Ohwada et al. (2006) \[[@CIT0008]\]    43            F        Lung, live, bone            Brain                    23.7                Cushingoid          \~2 years
  Capone et al. (2009) \[[@CIT0018]\]    45            M        Liver and lung              Brain, skull, meninges   24                  Nonfunctioning      6 months
  Velarde et al. (2015) \[[@CIT0014]\]   29            F        Liver and lung              Brain                    2                   −                   3 years
  Velarde et al. (2015) \[[@CIT0014]\]   37            M        Liver, lungs, lymph nodes   Brain                    8                   −                   3 years
  Velarde et al. (2015) \[[@CIT0014]\]   38            F        Liver and lung              Brain                    12                  −                   6 years
  Velarde et al. (2015) \[[@CIT0014]\]   44            M        Liver, bone, pleura         Brain                    7                   −                   6 years
  Velarde et al. (2015) \[[@CIT0014]\]   48            F        Lung                        Brain                    −                   −                   11 years
  Velarde et al. (2015) \[[@CIT0014]\]   60            M        Lung                        Brain                    Lost to follow-up   −                   2 years

###### 

**Pediatric** **patients with ACC and intracranial metastases**.

  Author                                   Age         Gender   Other metastases       Intracranial Location   Survival (months)   Functional Status   Brain metastasis from initial diagnosis
  ---------------------------------------- ----------- -------- ---------------------- ----------------------- ------------------- ------------------- -----------------------------------------
  Lefvre et al. (1983) \[[@CIT0016]\]      17 months   M        Lung                   Brain                   −                   −                   −
  Lefvre et al. (1983) \[[@CIT0016]\]      4 years     −        Brain                  −                       3                   −                   −
  Saracco et al., (1988) \[[@CIT0011]\]    1 day       M        Skin                   Brain                   −                   −                   4 months
  Ayass, (1991) \[[@CIT0004]\]             17 months   M        Lung, paraspinal       Brain                   −                   −                   −
  Lack et al. (1992) \[[@CIT0007]\]        10 years    M        Lung, liver, kidneys   Brain                   −                   −                   −
  Piniella (2000) \[[@CIT0009]\]           9 years     F        Brain                  −                       \>4                 −                   −
  Romaguera et al. (2001) \[[@CIT0010]\]   9 years     F        Lung                   Brain                   24                  Cushingoid          5 years
  Hertel et al. (2003) \[[@CIT0017]\]      14 years    F        Lung and thigh         Meninges                12                  Cushingoid          8 years
  Wagner et al. (2005) \[[@CIT0015]\]      10 years    M        Liver and lung         Brain                   9                   −                   3 years

We and others have previously shown that cell cycle activation is a predominant part of the ACC transcriptome, especially for aggressive ACCs \[[@CIT0002],[@CIT0019],[@CIT0026]\], and that a score based on mRNA expression of mitotic regulators *BUB1B* and *PINK1* predicts prognosis and overall survival \[[@CIT0024], [@CIT0025]\]. More recently, hypermethylation of another cell cycle regulator G0S2 (G0/G1 switch 2) was shown to be an independent predictor of recurrence-free survival and overall survival in ACC patients \[[@CIT0021]\]. Moreover, patients with hypermethylation of G0S2 (\>4.69% detected by the Epitect Methylation kit) combined with a *BUB1B--PINK1* score less than 5.2 resulted in intermediate or poor outcomes \[[@CIT0021]\]. Our patient had a *BUB1B--PINK1* score of 3.42 and demonstrated 97% methylation of G0S2. From the time of the discovery of her tumor to her death was slightly less than a year---a dismal prognosis, which correlated with these predictors.

Due to the variability in prognosis in patients with ACC, it can be often difficult to provide a clear treatment plan following radical surgery \[[@CIT0024]\]. While this patient presented with a hormonally active tumor and high Ki67%, both prognosticators of aggressive disease, she did not have widely metastatic disease at presentation. With substantial variability reported in Ki67 scoring even between expert laboratories \[[@CIT0027]\], additional predictive biomarkers such as the *BUB1B--PINK1* score and hypermethylation of G0S2 could be useful prognostic tools to estimate disease aggressiveness. While these biomarkers did not have an impact on our patient, identifying additional prognosticators will be helpful to further stratify prognosis in patients with aggressive ACC, and guide treatment as additional therapies become available in the future.
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